Covid 19 Research using Clinical Trials (Home Page)
ICU treatmentWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
Correlated MeSH Terms (2)
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
The Risk stratification in COVID-19 patients in the ICU (RISC-19-ICU) registry was founded
during the emerging SARS-CoV-2 pandemic. COVID-19 is a novel disease caused by infection with
the SARS-CoV-2 virus that was first described in December 2019. The disease has spread
exponentially in many countries and has reached global pandemic status within three months.
According to first experience, hospitalization was required in approximately 20 % of cases
and severe, life-threatening illness resulted in approximately 10 %. In some countries,
health care systems were overwhelmed by the rapid increase in critically ill patients that
far exceeded their capacity. It is thus of utmost importance to gain knowledge about the
characteristics and course of critically ill patients with COVID-19 and to stratify these
patients according to their risk for further deterioration. A key part of fighting this
pandemic is to exchange scientific information and advance our understanding of the disease.
The Risk stratification in COVID-19 patients in the ICU (RISC-19-ICU) registry aims to
collect an anonymized dataset to characterize patients that develop life-threatening critical
illness due to COVID-19 and make it accessible to collaborative analysis.
The data collected may be composed of a core dataset and/or an extended dataset. The core
dataset consists of a basic set of parameters, of which many are commonly generated during
treatment of critically ill patients with COVID-19 in an intensive care unit (the individual
parameters are marked yellow in the attached case report forms, and are clearly marked on the
electronic case report forms during data entry). The extended dataset consists of parameters
that may be measured during treatment of critically ill patients with COVID-19 in an
intensive care unit, depending on clinical practice, indication and availability of the
measurement method. The data accumulating in the registry as the pandemic or subsequent waves
develop are made available to the collaborators to support an optimal response to the
pandemic threat. The information gained on the initial characteristics and disease course via
the RISC-19-ICU registry may contribute to a better understanding of the risk factors for
developing critical illness due to COVID-19 and for an unfavorable disease course, and thus
support informed patient triage and management decisions.
Initial research questions are (I) to perform risk stratification of critically ill patients
with COVID-19 to find predictors associated with the development of critical illness due to
COVID-19: characterization of the study population, which are critically ill patients with
COVID-19: inflammation, oxygenation, circulatory function, among other parameters collected
in the registry, and (II) to perform risk stratification of critically ill patients with
COVID-19 to predict outcome after ICU admission (ICU mortality, ICU length of stay):
characterization of patients grouped by disease course in the ICU, based on inflammation,
oxygenation, circulatory function, and other parameters collected in the registry.
NCT04357275 Critical Illness ARDS Inflammatory Response COVID-19 Circulatory Shock Other: ICU treatment
Primary Outcomes
Measure: ICU mortality Time: During inclusion period
Secondary Outcomes
Measure: Hospital mortality Time: During inclusion period
Measure: ICU length of stay Time: During inclusion period
No related HPO nodes (Using clinical trials)